|
May 28
|
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform
|
|
May 27
|
Update: Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued
|
|
May 27
|
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results
|
|
May 27
|
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
|
|
May 27
|
Biogen strikes RNAi deal with City; Aurion withdraws IPO
|
|
May 27
|
Why Is Prothena Stock Trading Lower On Tuesday?
|
|
May 26
|
Prothena’s Phase III trial for AL amyloidosis treatment misses endpoint
|
|
May 23
|
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
|
|
Feb 22
|
Prothena Full Year 2024 Earnings: Misses Expectations
|
|
Feb 21
|
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
|
|
Feb 21
|
Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ...
|
|
Feb 20
|
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 20
|
Prothena: Q4 Earnings Snapshot
|
|
Feb 20
|
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
|
|
Feb 13
|
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
|
|
Dec 30
|
Prothena Announces Board of Directors Update
|
|
Sep 25
|
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
|
|
Aug 18
|
Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks
|
|
Jul 29
|
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 25
|
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|